-- Robert Preidt
FRIDAY, Dec. 6, 2013 (HealthDay News) -- A certain type of
diabetes drug may lower cancer risk in women with type 2 diabetes
by up to one-third, while another type may increase the risk,
according to a new study.
Cleveland Clinic researchers analyzed data from more than 25,600
women and men with type 2 diabetes to compare how two groups of
widely used diabetes drugs affected cancer risk.
The drugs included "insulin sensitizers," which lower blood
sugar and insulin levels in the body by increasing the muscle, fat
and liver's response to insulin. The other drugs analyzed were
"insulin secretagogues," which lower blood sugar by stimulating
beta cells in the pancreas to make more insulin.
The use of insulin sensitizers in women was associated with a 21
percent decreased cancer risk compared to insulin secretagogues,
the investigators found. Furthermore, the use of a specific insulin
sensitizer called thiazolidinedione was associated with a 32
percent decreased cancer risk in women compared to sulphonylurea,
an insulin secretagogue.
However, there were no significant differences between men who
used insulin sensitizers or secretagogues, according to the study
published online Dec. 5 in the journal
Diabetes, Obesity and Metabolism.
"What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," study leader Dr. Sangeeta Kashyap, an endocrinologist and associate professor of medicine at Cleveland Clinic's Endocrinology and Metabolism Institute, said in a clinic news release.
"By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. So, clearly, when prescribing anti-diabetic medications, it's important to consider the impact a drug has on fueling cancer growth," Kashyap added.
While the study found an association between specific types of
diabetes drugs and higher or lower cancer risk in women, it did not
establish a cause-and-effect relationship.
People with type 2 diabetes have higher rates of cancer
diagnosis and recurrence than people in the general population,
according to background information in the news release.
The American Diabetes Association has more about
diabetes and cancer.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.